IN2014CN02850A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02850A IN2014CN02850A IN2850CHN2014A IN2014CN02850A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A IN 2850CHN2014 A IN2850CHN2014 A IN 2850CHN2014A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A
- Authority
- IN
- India
- Prior art keywords
- methylbenzenesulfonamide
- indazol
- reconstitution
- pyrimidinyl
- methylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553454P | 2011-10-31 | 2011-10-31 | |
| PCT/US2012/060361 WO2013066616A1 (en) | 2011-10-31 | 2012-10-16 | Pazopanib formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02850A true IN2014CN02850A (pt) | 2015-07-03 |
Family
ID=48192602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2850CHN2014 IN2014CN02850A (pt) | 2011-10-31 | 2012-10-16 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9278099B2 (pt) |
| EP (1) | EP2773204A4 (pt) |
| JP (2) | JP6200893B2 (pt) |
| KR (1) | KR101993436B1 (pt) |
| CN (1) | CN104254249B (pt) |
| AU (1) | AU2012332952B2 (pt) |
| BR (1) | BR112014010551A2 (pt) |
| CA (1) | CA2852912A1 (pt) |
| HK (1) | HK1201685A1 (pt) |
| IN (1) | IN2014CN02850A (pt) |
| RU (1) | RU2616500C2 (pt) |
| WO (1) | WO2013066616A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145157A1 (en) * | 2014-03-28 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising pazopanib |
| CA3060247A1 (en) | 2017-04-17 | 2018-10-25 | Yale University | Compounds, compositions and methods of treating or preventing acute lung injury |
| WO2019053500A1 (en) | 2018-04-17 | 2019-03-21 | Alvogen Malta Operations (Row) Ltd | PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE FORM CONTAINING PAZOPANIB AND PROCESS FOR PREPARING THE SAME |
| CN112236146A (zh) | 2018-04-24 | 2021-01-15 | 盐野义制药株式会社 | 稳定性优良的固体制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH675537A5 (pt) | 1988-03-25 | 1990-10-15 | Ciba Geigy Ag | |
| ATE87476T1 (de) | 1988-11-10 | 1993-04-15 | Ciba Geigy Ag | Fluessige orale formulierung. |
| WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
| CZ12993U1 (cs) * | 2001-11-23 | 2003-02-10 | Glaxo Group Limited | Farmaceutický prostředek |
| RU2255730C1 (ru) * | 2003-10-14 | 2005-07-10 | Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") | Стабильная фармацевтическая суспензия азитромицина и способ ее получения |
| TWI374883B (en) * | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| DK1954281T3 (da) * | 2005-11-29 | 2011-05-16 | Glaxosmithkline Llc | Fremgangsmåde til cancerbehandling |
| CA2631173A1 (en) | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment method |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| US20100267787A1 (en) * | 2007-11-12 | 2010-10-21 | Gregory Harasymiw | Pharmaceutical Compositions |
| CL2008000374A1 (es) * | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
| WO2009128932A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Delivery of lfa-1 antagonists to the gastrointestinal system |
| US20100221247A1 (en) * | 2008-09-29 | 2010-09-02 | Robert Bender | Agents and methods for treatment of cancer |
| US20100291025A1 (en) * | 2009-04-13 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | Indazole inhibitors of tyrosine kinase |
| EP2298321A1 (en) * | 2009-08-26 | 2011-03-23 | Nordic Pharma | Novel pharmaceutical compositions for treating IBD |
| US8501811B2 (en) * | 2010-06-17 | 2013-08-06 | Washington University | TASPASE1 inhibitors and their uses |
-
2012
- 2012-10-16 WO PCT/US2012/060361 patent/WO2013066616A1/en active Application Filing
- 2012-10-16 EP EP12844715.8A patent/EP2773204A4/en not_active Withdrawn
- 2012-10-16 RU RU2014115289A patent/RU2616500C2/ru active
- 2012-10-16 CA CA2852912A patent/CA2852912A1/en not_active Abandoned
- 2012-10-16 BR BR112014010551A patent/BR112014010551A2/pt not_active IP Right Cessation
- 2012-10-16 US US14/353,141 patent/US9278099B2/en active Active
- 2012-10-16 KR KR1020147014294A patent/KR101993436B1/ko active IP Right Grant
- 2012-10-16 AU AU2012332952A patent/AU2012332952B2/en not_active Ceased
- 2012-10-16 IN IN2850CHN2014 patent/IN2014CN02850A/en unknown
- 2012-10-16 CN CN201280052742.8A patent/CN104254249B/zh not_active Expired - Fee Related
- 2012-10-16 JP JP2014538834A patent/JP6200893B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-04 HK HK15102188.1A patent/HK1201685A1/xx unknown
-
2016
- 2016-01-13 US US14/994,497 patent/US10080802B2/en active Active
-
2017
- 2017-05-10 JP JP2017093456A patent/JP6423484B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-22 US US16/109,143 patent/US10596263B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104254249A (zh) | 2014-12-31 |
| JP6200893B2 (ja) | 2017-09-20 |
| CA2852912A1 (en) | 2013-05-10 |
| AU2012332952A1 (en) | 2014-05-15 |
| BR112014010551A2 (pt) | 2017-05-02 |
| HK1201685A1 (en) | 2015-09-11 |
| RU2616500C2 (ru) | 2017-04-17 |
| RU2014115289A (ru) | 2015-12-10 |
| JP2014534215A (ja) | 2014-12-18 |
| AU2012332952B2 (en) | 2016-05-05 |
| US10080802B2 (en) | 2018-09-25 |
| US10596263B2 (en) | 2020-03-24 |
| US20140255505A1 (en) | 2014-09-11 |
| CN104254249B (zh) | 2017-02-15 |
| KR101993436B1 (ko) | 2019-06-26 |
| US9278099B2 (en) | 2016-03-08 |
| JP6423484B2 (ja) | 2018-11-14 |
| US20160120988A1 (en) | 2016-05-05 |
| EP2773204A1 (en) | 2014-09-10 |
| KR20140096082A (ko) | 2014-08-04 |
| JP2017197542A (ja) | 2017-11-02 |
| US20180360971A1 (en) | 2018-12-20 |
| WO2013066616A1 (en) | 2013-05-10 |
| EP2773204A4 (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| BR112012031297A2 (pt) | formulações de spray oral e métodos para administração de sildenafil | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| EA201291348A1 (ru) | Активаторы растворимой гуанилатциклазы | |
| SG10201804817TA (en) | Delayed release compositions of linaclotide | |
| MD20150050A2 (ro) | Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare | |
| RS53898B1 (en) | QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | |
| SG11201502622VA (en) | PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| MX357043B (es) | Inhibidores selectivos de pi3k delta. | |
| MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
| MX2014006026A (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| MX348606B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2). | |
| IL217052A0 (en) | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them | |
| NZ707160A (en) | A stable aqueous composition comprising human insulin or an analogue or derivative thereof | |
| MX2013010046A (es) | Administracion parenteral de tapentadol. | |
| UA116875C2 (uk) | Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять | |
| IN2014CN02850A (pt) | ||
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| MY186698A (en) | Solid forms of ceftolozane | |
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| GEP20146182B (en) | Delta crystalline form of arginine salt of perindopril, process for its preparation, and pharmaceutical com¬po¬- sitions containing it |